Omeros Corporation (OMER): Price and Financial Metrics


Omeros Corporation (OMER): $2.72

0.30 (+12.40%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add OMER to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

OMER POWR Grades


  • Growth is the dimension where OMER ranks best; there it ranks ahead of 96.51% of US stocks.
  • The strongest trend for OMER is in Growth, which has been heading up over the past 178 days.
  • OMER's current lowest rank is in the Momentum metric (where it is better than 12% of US stocks).

OMER Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for OMER is -0.34 -- better than merely 4.73% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -0.72 for Omeros Corp; that's greater than it is for only 4.78% of US stocks.
  • In terms of volatility of its share price, OMER is more volatile than 95.22% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Omeros Corp are APM, CLVS, SPRO, VERU, and LOGC.
  • OMER's SEC filings can be seen here. And to visit Omeros Corp's official web site, go to www.omeros.com.

OMER Valuation Summary

  • OMER's price/sales ratio is 11.8; this is 210.53% higher than that of the median Healthcare stock.
  • Over the past 145 months, OMER's EV/EBIT ratio has gone down 0.7.
  • OMER's price/sales ratio has moved down 144.2 over the prior 145 months.

Below are key valuation metrics over time for OMER.

Stock Date P/S P/B P/E EV/EBIT
OMER 2021-08-31 11.8 -4.1 -7.3 -10.7
OMER 2021-08-30 11.3 -4.0 -7.0 -10.4
OMER 2021-08-27 11.4 -4.0 -7.1 -10.4
OMER 2021-08-26 11.2 -3.9 -6.9 -10.3
OMER 2021-08-25 11.2 -3.9 -7.0 -10.3
OMER 2021-08-24 11.0 -3.9 -6.9 -10.2

OMER Growth Metrics

    The year over year revenue growth rate now stands at -37.18%.
  • Its 3 year net cashflow from operations growth rate is now at -63.75%.
  • Its 5 year net income to common stockholders growth rate is now at -15.86%.
OMER's revenue has moved up $69,980,000 over the prior 67 months.

The table below shows OMER's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 90.52 -109.914 -123.659
2021-06-30 86.63 -121.194 -139.419
2021-03-31 71.337 -131.199 -144.12
2020-12-31 73.813 -100.086 -138.061
2020-09-30 96.597 -104.693 -130.013
2020-06-30 100.339 -77.274 -108.013

OMER's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • OMER has a Quality Grade of B, ranking ahead of 81.69% of graded US stocks.
  • OMER's asset turnover comes in at 0.485 -- ranking 90th of 681 Pharmaceutical Products stocks.
  • HRTX, IRWD, and CHRS are the stocks whose asset turnover ratios are most correlated with OMER.

The table below shows OMER's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.485 0.987 -0.296
2021-03-31 0.446 0.987 -0.346
2020-12-31 0.495 0.988 -0.378
2020-09-30 0.699 0.987 -0.386
2020-06-30 0.962 0.989 -0.348
2020-03-31 1.041 0.991 -0.273

OMER Price Target

For more insight on analysts targets of OMER, see our OMER price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $37.43 Average Broker Recommendation 1.62 (Moderate Buy)

OMER Stock Price Chart Interactive Chart >

Price chart for OMER

OMER Price/Volume Stats

Current price $2.72 52-week high $16.62
Prev. close $2.42 52-week low $2.39
Day low $2.39 Volume 1,119,400
Day high $2.78 Avg. volume 690,945
50-day MA $4.38 Dividend yield N/A
200-day MA $7.65 Market Cap 170.63M

Omeros Corporation (OMER) Company Bio


Omeros Corporation is a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The company was founded in 1994 and is based in Seattle, Washington.


OMER Latest News Stream


Event/Time News Detail
Loading, please wait...

OMER Latest Social Stream


Loading social stream, please wait...

View Full OMER Social Stream

Latest OMER News From Around the Web

Below are the latest news stories about Omeros Corp that investors may wish to consider to help them evaluate OMER as an investment opportunity.

Needham Keeps Their Hold Rating on Omeros (OMER)

E ratio of -3.56.

Howard Kim on TipRanks | March 2, 2022

Omeros Corporation Reports Fourth Quarter and Year-End 2021 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation and immunologic diseases, including complement-mediated diseases and cancers, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2021, which include

Business Wire | March 1, 2022

Omeros Corporation''s (OMER) CEO Greg Demopulos On Q4 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | March 1, 2022

Omeros Non-GAAP EPS of -$0.37 misses by $0.31

Omeros press release (OMER): Q4 Non-GAAP EPS of -$0.37 misses by $0.31.At December 31, 2021, Omeros had $157.3 million of cash, cash equivalents and short-term investments available…

Seeking Alpha | March 1, 2022

How Much Of Omeros Corporation (NASDAQ:OMER) Do Institutions Own?

Every investor in Omeros Corporation ( NASDAQ:OMER ) should be aware of the most powerful shareholder groups...

Yahoo | March 1, 2022

Read More 'OMER' Stories Here

OMER Price Returns

1-mo -21.61%
3-mo -62.22%
6-mo -62.22%
1-year -82.09%
3-year -85.24%
5-year -82.01%
YTD -57.70%
2021 -54.99%
2020 1.38%
2019 26.48%
2018 -42.67%
2017 95.87%

Continue Researching OMER

Want to see what other sources are saying about Omeros Corp's financials and stock price? Try the links below:

Omeros Corp (OMER) Stock Price | Nasdaq
Omeros Corp (OMER) Stock Quote, History and News - Yahoo Finance
Omeros Corp (OMER) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5602 seconds.